Back to Agenda
Session 3: How Do QPPVs Have Oversight Over Local Markets?
Session Chair(s)
Elspeth McIntosh, MBA, RN
Director
Castle Pharmacovigilance Ltd, United Kingdom
Shahinaz Badr
Pharmacovigilance Consultant and PVQA Auditor - EMEA
Pharma Quality Europe, United Arab Emirates
Our PV systems are becoming increasingly complex with multiple stakeholders involved in, and collaborating with, the same or interlinked PV systems. This session will provide an insight into how QPPVs maintain oversight over local markets and their PV activities, helping to ensure an effective, compliant PV system.
Speaker(s)
Sina Schader, DrMed
AbbVie, Germany
Head of QPPV Office and EU QPPV
![Mette Stie Kallesoee](/_Images/member/Generic_Image_Missing-Profile.jpg)
Mette Stie Kallesoee
Hansa Biopharma, Sweden
QPPV
Angela Van Der Salm, PhD, MSc
DADA Consultancy B.V., Netherlands
Director PV, Managing partner
Strategies for Overcoming Challenges Faced by Non-EU/UK Local QPPVs
Yoon Jeon (Jamey) Kim, MSc, RPh
MSD, Panama
Cluster Pharmacovigilance Lead for Latin America
Have an account?